Related Experiment Videos
Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia
Insights
Granulocyte colony-stimulating factor (G-CSF) did not significantly alter mortality rates in pediatric acute leukemia patients experiencing chemotherapy-induced neutropenic septicemia. This study suggests G-CSF may not be essential for managing such severe infections.
Area of Science:
- Pediatric Oncology
- Hematology
- Infectious Diseases
Background:
- Granulocyte colony-stimulating factor (G-CSF) is known to accelerate neutrophil recovery after chemotherapy.
- Its routine prophylactic use is costly, prompting investigation into its role in specific clinical scenarios.
- Septicemia following chemotherapy-induced neutropenia in children with acute leukemia presents a significant clinical challenge.
Purpose of the Study:
- To evaluate the efficacy of G-CSF as an adjunct therapy for septicemia in children with acute leukemia experiencing neutropenia.
- To compare mortality rates in septicemic episodes with and without G-CSF intervention.
- To assess the impact of prophylactic G-CSF use in children receiving high-dose chemotherapy.
Main Methods:
- A retrospective study of 50 septicemia episodes in pediatric acute leukemia patients.
- Group A: 25 episodes without G-CSF (control).
- Group B: 16 episodes treated with G-CSF post-septicemia diagnosis.
- Group C: 9 episodes receiving prophylactic G-CSF during high-dose chemotherapy.
Main Results:
- Mortality rates per septicemia episode were 12.0% (Group A), 12.5% (Group B), and 0% (Group C).
- No statistically significant difference in mortality was observed between the groups (P > 0.5).
- G-CSF administration durations varied, with medians of 12 days (Group B) and 19 days (Group C).
Conclusions:
- G-CSF administration, whether as adjunct therapy or prophylactic measure, did not significantly reduce mortality in pediatric acute leukemia patients with neutropenic septicemia.
- The findings suggest that G-CSF may not be a critical factor in improving survival outcomes for this specific patient population and condition.
- Further research may be warranted to identify optimal supportive care strategies for neutropenic septicemia in pediatric oncology.
Abstract:
The granulocyte colony-stimulating factor (G-CSF) has been shown to accelerate recovery from severe neutropenia and to decrease the incidence of documented infections after intensive chemotherapy in cancer patients. However, the routine prophylactic use of G-CSF is expensive. This study was conducted to determine the role of G-CSF as adjunct therapy for septicemia following neutropenia caused by chemotherapy in children with acute leukemia. Fifty consecutive episodes of septicemia were studied involving 34 episodes of Gram-negative, 7 episodes of Gram-positive, 5 episodes of polymicrobial bacterial septicemia, one episode of fungemia, and 3 episodes of disseminated fungal infection. In the first 25 episodes, G-CSF was not used (group A). For the next 16 episodes, G-CSF 200 micrograms per square meter per day subcutaneously was given immediately after the septicemia was documented until the absolute neutrophil count was maintained at more than 1,500 per cubic millimeter (group B). Thereafter, G-CSF at the same dose as that of group B was prophylactically used in all the children who received high-dose cytosine arabinoside-containing regimens. Nine episodes of septicemia occurred (group C). The incidences of mortality per episode of septicemia in groups A, B, and C were 12.0% (3/25), 12.5% (2/16) and 0% (0/9), respectively. Statistically, there was no difference between the three groups overall and in pair-wise comparisons (all P > 0.5). The durations of G-CSF administration in group B ranged from 6 to 26 days with a median of 12 days and the durations of G-CSF administration in group C ranged from 10 to 23 days with a median of 19 days. With or without G-CSF, there may be no significant difference in the mortality of septicemia following neutropenia caused by chemotherapy in children with acute leukemia.